FDA Quality of Life Subcommittee
The first meeting of the new subcommittee of the Oncologic Drugs Advisory Committee will take place Feb. 10 (1"The Pink Sheet" Dec. 20, 1999, In Brief). The panel will discuss the definition of patient centered outcomes, clinical significance in interpretation of study results and approaches to statistical analysis of data. The meeting will take place at 8:00 a.m. at the Ramada Inn in Bethesda, Md
You may also be interested in...
FDA appoints new subcommittee to the Oncologic Drugs Advisory Committee to discuss quality of life issues. The committee will be made up of members of the Oncologic Drugs Advisory Committee as well as quality of life experts. Its first meeting is tentatively scheduled for Feb. 10
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials